| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
JP Morgan analyst Hardik Parikh maintains Viking Therapeutics (NASDAQ:VKTX) with a Overweight and lowers the price target fr...
Viking Therapeutics shares are rising Thursday. The clinical-stage biopharmaceutical company reported third-quarter earnings an...
Morgan Stanley analyst Michael Ulz maintains Viking Therapeutics (NASDAQ:VKTX) with a Overweight and raises the price target...
Viking Therapeutics (NASDAQ:VKTX) reported quarterly losses of $(0.81) per share which missed the analyst consensus estimate of...
Retail investors prepare for the first busy week in the Q3 earnings season, with Tesla, Netflix and Intel on deck.
HC Wainwright & Co. analyst Joseph Pantginis reiterates Viking Therapeutics (NASDAQ: VKTX) with a Buy and maintains $102...